Damon Runyon News

Maura L. Gillison, MD, PhD (Damon Runyon-Lilly Clinical Investigator ‘00-‘05) of the Ohio State University Comprehensive Cancer Center, Columbus, was elected a member of the National Academy of Medicine. This is one of the country’s highest and most prestigious honors in the fields of health and medicine. She is recognized for having made fundamental contributions to demonstrating the link between the human papillomavirus virus (HPV) and head and neck cancers.

The NIH announced the 2016 recipients of awards within its High-Risk, High-Reward Research program. These awards are designed to support scientists proposing highly innovative approaches to major contemporary challenges in biomedical research. Of 88 total awards this year, six were granted to Damon Runyon Scientists. 

2016 Pioneer Award

Christine Mayr, MD, PhD (Damon Runyon Innovator '13-'15), Memorial Sloan Kettering Cancer Center, New York

2016 NIH New Innovator Award

Dianne K. Newman, PhD (Damon Runyon Fellow ’88-‘89) of California Institute of Technology, Pasadena, was named one of 23 MacArthur Fellows for 2016. She is recognized for her innovative research investigating the role that bacteria have played in shaping the Earth and continue to play in modern biomedical contexts. The MacArthur Fellows Program awards five-year, unrestricted fellowships to individuals across all ages and fields who show exceptional merit and promise of continued creative work. 

Congratulations to the six researchers named recipients of The Lasker Awards, among the most respected prizes in medicine. William G. Kaelin, Jr., MD (Damon Runyon Board Member, Chair of the Physician-Scientist Training Award Committee) of Dana-Farber Cancer Institute, Boston, received the Albert Lasker Basic Medical Research Award for his work to understand the pathway cells use to sense and adapt to changes in oxygen levels which led to the development of potential drugs for heart attack, stroke, and kidney cancer. Bruce M.

Arvin C. Dar, PhD (Damon Runyon-Rachleff Innovator '14-'16) at the Icahn School of Medicine at Mount Sinai, reported that a “scaffolding protein” called the kinase suppressor of Ras (KSR) could be targeted as a way to disrupt signaling from mutant Ras protein. About 25 percent of human cancers have mutations in the Ras protein that disrupt growth signals and cause tumor development.  The researchers tested over 170 compounds and discovered that one could effectively slow cancer growth.

Colleen Delaney, MD, MSc (Damon Runyon Clinical Investigator ’07-’12) and colleagues at the Fred Hutchinson Cancer Research Center, Seattle, developed a method for using umbilical cord stem cells as a source of donor material for transplant. This is important because the majority of patients in need of a hematopoietic-cell transplant do not have a matched related donor. The advance is particularly valuable for minorities and people of mixed-race background.

Amit J. Sabnis, MD (Damon Runyon-Sohn Pediatric Cancer Fellow ’13-’17), of the University of California, San Francisco, and colleagues, demonstrated that cancer cells co-opt a cellular “chaperone” protein called HSP70 (heat-shock protein 70) to promote their growth. By blocking that pathway, the scientists were able to kill cells derived from patients with rhabdomyosarcoma (RMS), a rare muscle-tissue cancer that affects children.

Pavan Bachireddy, MD (Damon Runyon Physician-Scientist ’15-’19), Catherine J. Wu, MD (Damon Runyon-Lilly Clinical Investigator ’07-’12), and colleagues at the Dana-Farber Cancer Institute, Boston, reported that a new treatment approach, using repeated doses of the immunotherapy drug ipilimumab, may be able to restore a complete remission for some patients with advanced blood cancers that relapse after stem-cell transplant.

Daniel A. Heller, PhD (Damon Runyon Fellow ’10-’12), and colleagues at Memorial Sloan Kettering Cancer Center, New York, reported that radiation-guided nanoparticles may offer a new approach for penetrating the vascular barrier that often prevents current nanomedicines from reaching metastatic tumors. In a mouse model of lung cancer and metastatic melanoma and breast tumors, the nanoparticles selectively delivered chemotherapy drugs to the tumors. The researchers hope to translate these findings to clinical trials.

Damon Runyon Clinical Investigators Aude G. Chapuis, MD (’15-’17) of Fred Hutchinson Cancer Research Center, Seattle, Cassian Yee, MD (’01-’06), of M.D. Anderson Cancer Center, Houston, Jedd D. Wolchok, MD, PhD (’03-’08), of Memorial Sloan Kettering Cancer Center, New York, and colleagues, have successfully treated a patient with metastatic melanoma by combining two different types of immunotherapy, harnessing the patient’s own immune system to attack and destroy the cancer.